John Napoli
Psychiatry · Orchard Park, NYNPI 1225004997
Payments from drug & device makers
Across 487 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$646
- Sunovion Pharmaceuticals Inc.$552
- Neurocrine Biosciences, Inc.$420
- plus $2K from 13 others
What the payments were for
- Food & beverage$7,38898%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 86 | $1,579 |
| AbbVie(2 entities) | 129 | $1,244 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $1,002 |
| Otsuka America Pharmaceutical, Inc. | 39 | $646 |
| Sunovion Pharmaceuticals Inc. | 49 | $552 |
| Neurocrine Biosciences, Inc. | 21 | $420 |
| Vanda Pharmaceuticals Inc. | 21 | $404 |
| E.r. Squibb & Sons, L.L.C. | 11 | $399 |
| Teva Pharmaceuticals USA, Inc. | 18 | $383 |
| Lundbeck LLC | 14 | $320 |
| Axsome Therapeutics, Inc. | 7 | $174 |
| Johnson & Johnson | 5 | $114 |
| Corium, LLC | 8 | $109 |
| Supernus Pharmaceuticals, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Bausch Health US, LLC | 2 | $32 |
| Eisai Inc. | 1 | $15 |
| Indivior Inc. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$235
How this compares
$7,523 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 67 | $93,697 |
| RexultiBrexpiprazole | 26 | $47,910 |
| Abilify MaintenaAripiprazole | 13 | $37,760 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $30,930 |
| TrintellixVortioxetine Hydrobromide | 55 | $27,757 |
| CaplytaLumateperone Tosylate | 14 | $23,815 |
| FetzimaLevomilnacipran Hcl | 18 | $8,599 |
| XareltoRivaroxaban | 11 | $6,162 |
| Lurasidone Hcl | 45 | $6,022 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 40 | $3,924 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 75 | $2,752 |
| Methylphenidate Hcl | 66 | $2,009 |
| Duloxetine Hcl | 136 | $1,957 |
| Bupropion XlBupropion Hcl | 104 | $1,927 |
| Quetiapine Fumarate | 142 | $1,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,244 | $102,29685 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $646 | $85,67039 claims |
| Axsome Therapeutics, Inc.Auvelity | $174 | $30,93023 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $27,75755 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,002 | $23,81514 claims |
| Johnson & JohnsonXarelto | $114 | $6,16211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Orchard Park
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.